CWA Asset Management Group LLC Purchases 3,883 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

CWA Asset Management Group LLC lifted its position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 27.0% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 18,279 shares of the company’s stock after buying an additional 3,883 shares during the quarter. CWA Asset Management Group LLC’s holdings in Harmony Biosciences were worth $629,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the business. GAMMA Investing LLC raised its stake in Harmony Biosciences by 92.6% in the 4th quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock worth $31,000 after purchasing an additional 436 shares in the last quarter. CWM LLC increased its holdings in shares of Harmony Biosciences by 111.7% during the third quarter. CWM LLC now owns 1,469 shares of the company’s stock worth $59,000 after purchasing an additional 775 shares during the period. Quantbot Technologies LP acquired a new stake in shares of Harmony Biosciences in the third quarter valued at approximately $74,000. Quarry LP bought a new stake in shares of Harmony Biosciences in the second quarter valued at approximately $62,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in Harmony Biosciences by 21.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,056 shares of the company’s stock worth $80,000 after buying an additional 360 shares in the last quarter. Institutional investors own 86.23% of the company’s stock.

Harmony Biosciences Stock Performance

NASDAQ HRMY opened at $34.53 on Thursday. The firm’s fifty day moving average price is $34.00 and its two-hundred day moving average price is $34.58. The stock has a market cap of $1.97 billion, a PE ratio of 16.36, a PEG ratio of 0.60 and a beta of 0.78. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24. Harmony Biosciences Holdings, Inc. has a fifty-two week low of $28.14 and a fifty-two week high of $41.61.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings data on Tuesday, October 29th. The company reported $0.79 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.15. The business had revenue of $186.00 million for the quarter, compared to analyst estimates of $184.07 million. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. Harmony Biosciences’s quarterly revenue was up 16.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.63 EPS. On average, equities analysts expect that Harmony Biosciences Holdings, Inc. will post 2.36 EPS for the current fiscal year.

Insider Activity

In other Harmony Biosciences news, insider Jeffrey Dierks sold 21,496 shares of the company’s stock in a transaction that occurred on Tuesday, October 29th. The shares were sold at an average price of $40.47, for a total value of $869,943.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 30.80% of the stock is currently owned by insiders.

Analysts Set New Price Targets

HRMY has been the subject of several analyst reports. Oppenheimer reaffirmed an “outperform” rating and issued a $59.00 price objective (up from $56.00) on shares of Harmony Biosciences in a report on Wednesday, October 30th. Raymond James reaffirmed an “outperform” rating and set a $40.00 price objective on shares of Harmony Biosciences in a research report on Thursday, October 10th. Needham & Company LLC reissued a “buy” rating and issued a $52.00 target price on shares of Harmony Biosciences in a report on Tuesday, October 29th. Mizuho upped their price target on shares of Harmony Biosciences from $42.00 to $52.00 and gave the stock an “outperform” rating in a report on Thursday, October 10th. Finally, Cantor Fitzgerald lifted their price objective on shares of Harmony Biosciences from $51.00 to $58.00 and gave the company an “overweight” rating in a research note on Wednesday, October 30th. One research analyst has rated the stock with a sell rating and eight have given a buy rating to the company. According to data from MarketBeat.com, Harmony Biosciences presently has an average rating of “Moderate Buy” and a consensus price target of $52.00.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.